Navigation Links
LS9, Inc. Appoints Bill Haywood Chief Executive Officer
Date:10/8/2008

SOUTH SAN FRANCISCO, Calif., Oct. 8 /PRNewswire/ -- LS9, Inc., the Renewable Petroleum Company(TM), today announces it has appointed Bill Haywood as Chief Executive Officer. Mr. Haywood brings over 30 years of experience in the fuels manufacturing business and a proven track record of planning, engineering, execution and start-up of major projects within the energy sector.

"The coming year will be pivotal to LS9 as the company delivers significant achievements in the development of second-generation biofuels," said Noubar Afeyan, Managing Partner of Flagship Ventures and Chairman of the LS9 Board of Directors. "Bill brings with him the ideal combination of project development, organizational optimization and investment management expertise the company needs as it transitions from development to production. His extensive relationships in the transportation fuels sector and his deep understanding of strategic partnerships are an ideal complement to the talented scientific team at LS9. The Board is extremely pleased to have Bill at the helm of the company."

Prior to joining LS9, Mr. Haywood served as Senior Vice President of Refining for Tesoro Petroleum, where he was responsible for seven refineries and over $20 billion in revenue. Under his leadership, Tesoro became a leading independent refiner by integrating refinery acquisitions, driving operational excellence and building over $1 billion in capital projects. During this period, shareholder value increased by more than 86%.

"I can't think of a more exciting opportunity than joining LS9 as we prepare to move this important technology to commercial production and become the first advanced biofuels company to reach the market," said Mr. Haywood. "I look forward to merging knowledge of the traditional transportation fuels business with synthetic biology to help bring LS9's renewable fuels and chemicals into the pipeline and to the consumer."

About LS9

LS9, Inc., the Renewable Petroleum Company(TM), is a privately-held industrial biotechnology company pursuing the commercial development of renewable fuels and chemicals. LS9 is applying synthetic biology to produce proprietary biofuels that are compatible with existing fuel distribution and consumer infrastructure and high value industrial chemicals. LS9 is the pioneer in the commercial development of fermentation derived hydrocarbon biofuels and its patent-pending Renewable Petroleum(TM) products are custom engineered in the lab to address immediate market needs for clean energy alternatives to petroleum. The company was founded in 2005 and venture capital firms Flagship Ventures, Khosla Ventures, and Lightspeed Venture Partners have provided funding to date. LS9 is headquartered in South San Francisco, California.


'/>"/>
SOURCE LS9, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
2. CPC of America, Inc. to Explore Strategic Alternatives; Appoints FTI Capital Advisors to Assess Potential Opportunities
3. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development
6. Neurofocus Appoints Stephen Kosslyn to Its Advisory Board
7. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
8. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
9. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
10. China Yingxia International, Inc. Appoints New Vice President of Finance
11. SoluBest Appoints Michael Sheckler, MBA, as CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), ... for operable and inoperable solid tumor cancers, announced today ... of NW Bio, will present at the Phacilitate Immunotherapy ... Hyatt Regency Hotel in Miami, Florida ... entitled "New Therapeutic Approaches – Expanding the Reach of ...
(Date:1/18/2017)... January 18, 2017 According to a new market research ... Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) ... reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, growing ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... ... ... Executive search firm Slone Partners proudly supports the SCOPE ... of the clinical trials segment. Hosted in Miami, this conference brings together renowned ... , As executive talent specialists in the industries central to clinical trials, ...
(Date:1/18/2017)... ... 2017 , ... MYOLYN, which creates medical technology for people ... to the FDA, requesting clearance of the MyoCycle Home and the MyoCycle Pro ... , The submission marks a major milestone for the technology startup. MYOLYN spun ...
Breaking Biology Technology:
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported ... to over 40 granted and pending patents. ... , The Company,s IP portfolio ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... hardware components needed to estimate the force and pressure applied to touch ...
(Date:12/7/2016)... 7, 2016   Veridium , a leader ... of new CEO James Stickland . Stickland, ... of experience, has served in senior executive roles ... specialized in expanding a pipeline of venture capital ... most recently served as managing director of U.K.-based ...
(Date:12/6/2016)... Dec. 6, 2016 Valencell , the leading ... has seen a third consecutive year of triple digit ... in 2016 with a 360 percent increase in companies ... increase was driven by sales of its wrist and ... in its technology for hearables for fitness and healthcare ...
Breaking Biology News(10 mins):